Enhanced CTL epitope-containing HIV-1 reverse transcriptase polypeptides
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsJay A. Berzofsky, Takahiro Okazaki
Life of this patent
Estimating the term…
Abstract
The present invention provides peptides and proteins for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an HLA epitope-enhanced vaccine. These findings define a critical balance between MHC affinity and receptor crossreactivity required for effective epitope enhancement and also demonstrate construction and efficacy of such a component of a new generation vaccine.
Claims27
An immunostimulating peptide comprising an amino acid sequence X1LYQYMDDV (SEQ ID NO:1), wherein X1 is any hydrophobic amino acid.
An immunostimulating peptide or protein comprising the sequence X1X2LYQYMDDVX3 (SEQ ID NO:4) wherein X1 is a sequence of amino acid residues of between 0 and 200 residues in length;
- X2 is any hydrophobic amino acid;
- and X3 is a sequence of amino acid residues of between 0 and 200 residues in length.
A peptide or protein comprising an amino acid sequence X1LYQYMDDV (SEQ ID NO:1), wherein X1 is any hydrophobic amino acid.
An immunostimulating peptide consisting of an amino acid sequence X1LYQYMDDV (SEQ ID NO:1), wherein X1 is any hydrophobic amino acid.
A peptide or protein comprising an amino acid sequence X1X2YQYMDDVX3 (SEQ ID NO:23) wherein X1 is a sequence of amino acid residues of between 0 and 200 residues in length;
- X2 is any hydrophobic amino acid;
- and X3 is a sequence of amino acid residues of between 0 and 200 residues in length.
Dependencies are inferred from the claim text.